Kotredes Kevin P, Oblak Adrian, Pandey Ravi S, Lin Peter Bor-Chian, Garceau Dylan, Williams Harriet, Uyar Asli, O'Rourke Rita, O'Rourke Sarah, Ingraham Cynthia, Bednarycek Daria, Belanger Melisa, Cope Zackary, Foley Kate E, Logsdon Benjamin A, Mangravite Lara M, Sukoff Rizzo Stacey J, Territo Paul R, Carter Gregory W, Sasner Michael, Lamb Bruce T, Howell Gareth R
The Jackson Laboratory, Bar Harbor, ME, United States.
Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States.
Front Aging Neurosci. 2021 Oct 11;13:735524. doi: 10.3389/fnagi.2021.735524. eCollection 2021.
Late-onset Alzheimer's disease (AD; LOAD) is the most common human neurodegenerative disease, however, the availability and efficacy of disease-modifying interventions is severely lacking. Despite exceptional efforts to understand disease progression legacy amyloidogenic transgene mouse models, focus on disease translation with innovative mouse strains that better model the complexity of human AD is required to accelerate the development of future treatment modalities. LOAD within the human population is a polygenic and environmentally influenced disease with many risk factors acting in concert to produce disease processes parallel to those often muted by the early and aggressive aggregate formation in popular mouse strains. In addition to extracellular deposits of amyloid plaques and inclusions of the microtubule-associated protein tau, AD is also defined by synaptic/neuronal loss, vascular deficits, and neuroinflammation. These underlying processes need to be better defined, how the disease progresses with age, and compared to human-relevant outcomes. To create more translatable mouse models, MODEL-AD (Model Organism Development and Evaluation for Late-onset AD) groups are identifying and integrating disease-relevant, humanized gene sequences from public databases beginning with and 7H, two of the most powerful risk factors present in human LOAD populations. Mice expressing endogenous, humanized and 7H gene sequences were extensively aged and assayed using a multi-disciplined phenotyping approach associated with and relative to human AD pathology. Robust analytical pipelines measured behavioral, transcriptomic, metabolic, and neuropathological phenotypes in cross-sectional cohorts for progression of disease hallmarks at all life stages. PET/MRI neuroimaging revealed regional alterations in glycolytic metabolism and vascular perfusion. Transcriptional profiling by RNA-Seq of brain hemispheres identified sex and age as the main sources of variation between genotypes including age-specific enrichment of AD-related processes. Similarly, age was the strongest determinant of behavioral change. In the absence of mouse amyloid plaque formation, many of the hallmarks of AD were not observed in this strain. However, as a sensitized baseline model with many additional alleles and environmental modifications already appended, the dataset from this initial MODEL-AD strain serves an important role in establishing the individual effects and interaction between two strong genetic risk factors for LOAD in a mouse host.
晚发型阿尔茨海默病(AD;LOAD)是最常见的人类神经退行性疾病,然而,改善病情的干预措施的可用性和有效性严重不足。尽管人们为了解疾病进展付出了巨大努力,但传统的淀粉样蛋白生成转基因小鼠模型仍需关注采用能更好模拟人类AD复杂性的创新小鼠品系来推动疾病转化,以加速未来治疗方法的开发。人类群体中的LOAD是一种受多基因和环境影响的疾病,许多风险因素共同作用,产生与常见小鼠品系中早期和侵袭性聚集形成常常掩盖的疾病过程平行的疾病进程。除了淀粉样斑块的细胞外沉积和微管相关蛋白tau的包涵体外,AD还表现为突触/神经元丧失、血管缺陷和神经炎症。这些潜在过程需要得到更好的定义,了解疾病如何随年龄进展,并与人类相关结果进行比较。为了创建更具可转化性的小鼠模型,MODEL-AD(晚发型AD的模式生物开发与评估)团队正在从公共数据库中识别并整合与疾病相关的人源化基因序列,首先是APOE和7H,这是人类LOAD群体中存在的两个最强大的风险因素。表达内源性人源化APOE和7H基因序列的小鼠经过长期饲养,并使用与人类AD病理学相关且相对于人类AD病理学的多学科表型分析方法进行检测。强大的分析流程在横断面队列中测量行为、转录组、代谢和神经病理学表型,以了解所有生命阶段疾病特征的进展。PET/MRI神经成像揭示了糖酵解代谢和血管灌注的区域改变。通过对脑半球进行RNA-Seq转录谱分析,确定性别和年龄是基因型之间变异的主要来源,包括AD相关过程的年龄特异性富集。同样,年龄是行为变化的最强决定因素。在没有小鼠淀粉样斑块形成的情况下,该品系未观察到许多AD特征。然而,作为一个已经附加了许多额外等位基因和环境修饰的敏感基线模型,来自这个初始MODEL-AD品系的数据集在确定小鼠宿主中LOAD的两个强大遗传风险因素之间的个体效应和相互作用方面发挥着重要作用。